Based on our experience that prototypical non‐endometrioid carcinomas do not harbor POLE mutations [13, 33], testing of non‐endometrioid carcinomas in the IR (9 cases) and HR (22 cases) groups could be further restricted to cases with ambiguous/mixed histology, POLE phenotype [34], and cases with multiple subclonal p53 patterns. This evidence concerns the gene TP53 and endometrioid adenocarcinoma.